Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | UBE2N | P61088 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258606 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10258140 | 0.89 | KMT2A (0.62) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10291253 | 0.88 | KMT2A (0.48) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10258100 | 0.88 | L3MBTL1 (0.63) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL13259457 | 0.88 | L3MBTL1 (0.63) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10266912 | 0.87 | GAA (0.61) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL18780759 | 0.87 | POLB (0.60) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10258089 | 0.87 | POLB (0.60) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL13259371 | 0.86 | GAA (0.47) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT | |
| SCHEMBL10266917 | 0.86 | GAA (0.47) | ALDH1A1CYP1A2CYP3A4UBE2NMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | ALDH1A1 331/4885CYP1A2 116/4885CYP3A4 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.